在糖尿病前期患者中,SUCNR1 调节胰岛素分泌,而葡萄糖则提高了糖酸盐反应
Joan Sabadell-Basallote1,2,3,4, Brenno Astiarraga1,2, Carlos Castaño1,2
1Unitat de Recerca, Hospital Universitari Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain.
The Journal of clinical investigation
|May 7, 2024
概括
酸盐受体1 (SUCNR1) 调节胰腺β细胞中的胰岛素分泌. 这一途径对于维持葡萄糖耐受性至关重要,特别是在2型糖尿病和糖尿病前期状态下.
科学领域:
- 代谢研究的研究.
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 胰腺β细胞功能障碍是2型糖尿病发病的核心原因.
- 鉴定胰岛素分泌的新型调节剂对于治疗开发至关重要.
研究的目的:
- 调查胰腺β细胞中酸盐受体1 (SUCNR1) 的作用及其对胰岛素分泌的调节.
- 探索苏酸盐/SUCNR1轴作为糖尿病潜在的治疗点.
主要方法:
- 在高血糖条件下的人类和小鼠β细胞中检查了SUCNR1的表达.
- 通过使用SUCNR1-Gq-PKC依赖机制研究了酸盐对人类β细胞胰岛素分泌的影响.
- 评估高脂肪饮食中患有β细胞特异性Sucnr1缺乏症的小鼠的葡萄糖耐受性和胰岛素分泌.
主要成果:
- SUCNR1在β细胞中表达,并在高血糖期间升调.
- 苏酸通过人类β细胞中的SUCNR1-Gq-PKC通路刺激胰岛素分泌.
- 在饮食引起的胰岛素抵抗中,β细胞特异性Sucnr1缺乏会损害葡萄糖耐受性和胰岛素分泌.
结论:
- 酸盐/SUCNR1轴被高葡萄糖激活,代表GPCR介导的胰岛素分泌放大通路.
- 在饮食引起的胰岛素抵抗中,SUCNR1对于维持胰岛素分泌至关重要.
- 这一途径与在糖尿病前期观察到的高胰岛素血症有关.
相关概念视频
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Hormones Regulating Blood Glucose
3.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.3K
Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Insulin Secretory Vesicles
4.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.9K
Glucose Homeostasis: Regulation of Blood Glucose
1.6K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.6K
Oral Hypoglycemic Agents: Sulfonylureas
205
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
205


